Hard Decisions in RA
Sponsored by RheumNow
Eight debates and perspectives on Hard Decisions in RA now available.
RX Updates
When do you consider switching vs cycling in patients with RA after first TNFi failure?
Sponsored by AbbVie Medical Affairs
Watch rheumatologists Dr. Roy Fleischmann and Dr. Janet Pope discuss treatment options for patients with RA who have failed a TNFi. The experts consider switching to an alternate MOA vs cycling to another TNFi.
Composite Measure to Inform Management of Bio-naïve Patients with Psoriatic Arthritis
Sponsored by AbbVie Medical Affairs
Listen as rheumatologists Dr. Philip Mease and Dr. Saakshi Khattri share their insights on using composite measures to manage patients with psoriatic arthritis. In this podcast, they discuss four composite measures used in trials of an IL-23 inhibitor.
Mechanism of Action of an Interleukin (IL)–23 Inhibitor Monoclonal Antibody in Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis
Sponsored by Janssen Biotech, Inc.
This disease education update from Janssen provides an overview of an interleukin (IL)-23 inhibitor.
Disease Modification in Lupus and Lupus Nephritis: Modifying the Natural Course of the Disease
Sponsored by GSK US Medical Affairs
Discover how you can apply the concept of disease modification in lupus and lupus nephritis to help treat patients in your clinical practice. View our infographic and walk through an interactive patient journey towards disease modification.
Also, listen to leading expert Dr. Michelle Petri to learn about scientific advances in monitoring for renal damage accrual in lupus nephritis.
Heart to Heart: Experts Discuss Cardiovascular Risk in Rheumatoid Arthritis
Sponsored by AbbVie Medical Affairs
Tune in as rheumatologists Dr. Christina Charles-Schoeman and Dr. Roy Fleischmann discuss how you can help mitigate cardiovascular risk in your patients with rheumatoid arthritis.
Women in Rheumatology: Gender Issues in Disease and Management
Sponsored by Bristol Myers Squibb
Nine videos discussing gender differences in axSpA, PsA, Vasculitis, Lung Disease, Osteoporosis, Disparities in Healthcare, and Rheumatologic Activity and Treatment, are now available.
Biologics in Lupus - Why, Who and When?
Sponsored by GSK US Medical Affairs
Leading experts from the SLE Educators’ Network discuss how biologic therapies may help address key unmet needs in lupus, while highlighting how clinicians can identify the most appropriate patients for biologic treatment.
A Rheum & Derm Perspective on Treating PsA and Moderate-to-Severe PsO
Sponsored by Lilly USA
Dr. Mease and Dr. Armstrong discuss a multidisciplinary approach and important considerations when treating patients with joint and skin concerns. Ages 18+; for HCPs only.
Solving Still's Disease
Dr. Jack Cush reviews the history, manifestations, diagnosis and treatment of Still's disease.
An Anti-IL-23 in Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis
Sponsored by Janssen Biotech, Inc
Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are disorders of the immune system driven primarily by dysregulated T cells. Studies suggest that the Interleukin (IL)-23/Th-17 axis is one of the pathways involved in the pathogenesis of PsO and PsA.
Expert Perspectives on SLE Pathophysiology and the Importance of Changing the Course of Disease
Sponsored by GSK US Medical Affairs
Leading experts from the SLE Educators' Network take us through the pathophysiology of SLE as we understand it today, and discuss the need to change the course of disease as a key treatment goal.